Safety, tolerability, and pharmacokinetic interactions between single-dose TMC207 and steady-state efavirenz in healthy volunteers: AIDS Clinical Trials Group (ACTG) Study.

Post Date:

2012-04-15

Countries:

Publication:

Journal of Acquired Immune Deficiency Syndromes

Summary:

Background: Drug-drug interactions complicate management of coinfection with HIV-1 and Mycobacterium tuberculosis. Bedaquiline (formerly TMC207), an investigational agent for the treatment of tuberculosis, is metabolized by cytochrome P450 (CYP) 3A which may be induced by the antiretroviral drug efavirenz.

Methods: This was a phase 1 pharmacokinetic drug interaction trial. Each healthy volunteer received two 400 mg doses of bedaquiline, the first alone and the second with concomitant steady-state efavirenz. Plasma pharmacokinetic sampling for bedaquiline and its N-monodesmethyl metabolite was performed over 14 days after each bedaquiline dose. Steady-state efavirenz pharmacokinetics were also determined. Efavirenz metabolizer status was based on CYP2B6 composite 516/983 genotype.

Citation:

Dooley KE, Park J-G, Swindells S, Allen R, Haas DW, Aweeka F, Gupta A, Lizak P, Qasba S, Cramer Y, van Heeswijk R, Flexner C. Safety, tolerability, and pharmacokinetic interactions between single-dose TMC207 and steady-state efavirenz in healthy volunteers: AIDS Clinical Trials Group (ACTG) Study. J Acquir Immune Defic Syndr. 2012 Apr; 15;59(5):455-62. PMCID:PMC3302922

Staff:

Kelly Dooley, MD

Amita Gupta, MD, MHS

Collaborators:

Harvard School of Public Health, Boston, MA

University of Nebraska Medical Center, Omaha, NE

ACTG Operations Center, Silver Spring, MD

Vanderbilt University School of Medicine, Nashville, TN

University of California, San Francisco, CA

Division of AIDS, National Institutes of Health, Bethesda, MD

Tibotec, BVBA, Mechelen, Belgium

Access full article